IPI Legacy Liquidation Co Past Earnings Performance
Past criteria checks 0/6
IPI Legacy Liquidation Co's earnings have been declining at an average annual rate of -23.8%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 118.6% per year.
Key information
-23.8%
Earnings growth rate
116.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 118.6% |
| Return on equity | n/a |
| Net Margin | -353.9% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Investors Still Aren't Entirely Convinced By Impel Pharmaceuticals Inc.'s (NASDAQ:IMPL) Revenues Despite 50% Price Jump
Apr 17
The Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Full-Year Results Are Out And Analysts Have Published New Forecasts
Mar 30Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Analysts Just Slashed This Year's Revenue Estimates By 12%
Mar 26Impel NeuroPharma GAAP EPS of -$1.09 misses by $0.04, revenue of $2.8M misses by $1.04M
Aug 15Impel stock rises as dosing begins in mid-stage trial of INP105 for agitation in autistic people
Jul 19Impel Pharmaceuticals: Under The Radar Despite Upside Potential
Jun 28Impel NeuroPharma reports Q1 results
Jun 07Revenue & Expenses Breakdown
How IPI Legacy Liquidation Co makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 21 | -74 | 77 | 4 |
| 30 Jun 23 | 19 | -92 | 81 | 7 |
| 31 Mar 23 | 15 | -109 | 80 | 11 |
| 31 Dec 22 | 13 | -106 | 78 | 11 |
| 30 Sep 22 | 8 | -108 | 77 | 15 |
| 30 Jun 22 | 5 | -102 | 74 | 18 |
| 31 Mar 22 | 2 | -92 | 65 | 20 |
| 31 Dec 21 | 1 | -77 | 51 | 21 |
| 30 Sep 21 | 0 | -66 | 36 | 25 |
| 30 Jun 21 | 0 | -50 | 22 | 25 |
| 31 Mar 21 | 0 | -48 | 19 | 26 |
| 31 Dec 20 | 0 | -46 | 17 | 28 |
Quality Earnings: IMPL.Q is currently unprofitable.
Growing Profit Margin: IMPL.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IMPL.Q is unprofitable, and losses have increased over the past 5 years at a rate of 23.8% per year.
Accelerating Growth: Unable to compare IMPL.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMPL.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: IMPL.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/08 03:03 |
| End of Day Share Price | 2024/04/05 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
IPI Legacy Liquidation Co is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yatin Suneja | Guggenheim Securities, LLC |
| Dana Flanders | Guggenheim Securities, LLC |
| Kenneth Cacciatore | TD Cowen |